09/10/2026
Bispecific T-cell engager (BiTE) therapies have moved beyond research settings into both academic and community oncology practices. Yet some practices hesitate to offer them due to concerns about complexity, cost and potential side effects.
In response, American Oncology Network (AON) created the Bispecific T-Cell Therapy Educational Series, a four-part virtual program that runs through December to provide practical guidance on administering and managing BiTE therapies in the community setting.
And, AON Vice President of Pharmacy Operations, Melody Chang, RPh, MBA, BCOP, who runs the program, discusses BiTE therapies, emerging treatments and how BiTE can be implemented cost-effectively in community oncology settings in our latest blog post, here: https://hubs.li/Q04x33RV0